ASTM E2526-2008(2013)
评估猪肾细胞和人类肝癌细胞中纳米粒子材料细胞毒素的标准试验方法

Standard Test Method for Evaluation of Cytotoxicity of Nanoparticulate Materials in Porcine Kidney Cells and Human Hepatocarcinoma Cells

非常抱歉，我们暂时无法提供预览，您可以试试： 免费下载 ASTM E2526-2008(2013) 前三页，或者稍后再访问。

注意： 点击下载后，生成下载文件时间比较长，请耐心等待......

标准号

ASTM E2526-2008(2013)

发布日期

2008年

实施日期

废止日期

无

国际标准分类号

07.100.10 (Medical microbiology)

发布单位

US-ASTM

适用范围

5.1x00a0;Assessing the propensity of a nanomaterial to cause cytotoxicity to the cells of a target organ can assist in preclinical development.

5.2x00a0;The standard historical cytotoxicity testing of materials and extracts of materials has used fibroblasts and is well documented in Practice F813, Test Method F895, and ISO 10993-5. The use of macrophages and micron size particles has also provided information on cytotoxicity and stimulation using Practice F1903.

5.3x00a0;This test method adds to the cytotoxicity test protocols by using target organ cells. Two quantitative assays measuring LDH leakage and MTT reduction are used to estimate cytotoxicity.

5.4x00a0;This test method may not be predictive of events occurring in all types of nanomaterial applications and the user is cautioned to consider the appropriateness of the test for various types of nanomaterial applications. This procedure should only be used to compare the cytoxicity of a series of related nanomaterials. Meaningful comparison of unrelated nanomaterials is not possible without additional characterization of physicochemical properties of each individual nanomaterial in the assay matrix.

1.1x00a0;This test method provides a methodology to assess the cytotoxicity of suspensions of nanoparticulate materials in porcine proximal tubule cells (LLC-PK1) and human hepatocarcinoma cells (Hep G2) which represents potential target organs following systemic administration

1.2x00a0;This test method is part of the in vitro preclinical characterization cascade.

1.3x00a0;This test method consists of a protocol utilizing two methods for estimation of cytotoxicity, 3-(4,5-Dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) reduction and lactate dehydrogenase (LDH) release.

1.4x00a0;The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

1.5x00a0;This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.

ASTM E2526-2008(2013) 中可能用到的仪器设备